IN30758 / InxMed - LARVOL DELTA

IN30758, an integrin-targeted antibody drug conjugate (ADC) demonstrating strong therapeutic effects in multiple solid tumors (AACR 2026) - "Various animal models, including cell line-derived xenograft (CDX) and patient-derived xenograft (PDX) trials, were conducted to assess the tumor growth inhibition effects of IN30758, revealing that the ADC shows promising sensitivity across multiple solid tumors. Currently, the Investigational New Drug (IND) package, which includes preclinical efficacy, pharmacokinetics, and toxicity data, has been compiled, with the IND application expected to be submitted in December 2025."

ADC • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor

InxMed Presents Data regarding Potential Novel Way to Improve Therapeutic Window of ADC by Ifebemtinib and FIC ADC at 15th Annual World ADC (PRNewswire) - "InxMed...is presenting preclinical data at 15th Annual World ADC Conference in San Diego regarding ifebemtinib (ifebe, IN10018), a highly potent and selective oral inhibitor of focal adhesion kinase (FAK), to enhance efficacy and improve safety of ADCs, and IN30758, a First-in-class ADC for treatment of multiple solid tumors including DXD resistant cancers....Preclinical data demonstrated that ifebemtinib was able to reduce the fibrotic barrier, enhance the penetration of ADC, and boost efficacy....IND for Ifebemtinib in combination with ADC will be submitted to China CDE in Nov 2024....Preclinically, IN30758 exhibits robust in vivo efficacy in CDX and PDX models of multiple cancers and well tolerated in cynomolgus monkeys. IN30758 will be ready for IND submission in 2025."

New trial • Preclinical • Solid Tumor